Gene Delivery Using Physical Methods - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 124

[241] Wirtz R. Die ionentheraphie in der augenheilkunde. Klin Monatsbl Augenheilkd
1908;46:543-79.
[242] Bejjani RA, Andrieu C, Bloquel C, Berdugo M, BenEzra D, Behar-Cohen F. Electrically
assisted ocular gene therapy. Surv Ophthalmol 2007;52:196-208.
[243] Monteiro-Riviere NA, Inman AO, Riviere JE. Identification of the pathway of ionto-
phoretic drug delivery: light and ultra-structural studies using mercuric chloride in pigs.
Pharm Res 1994;11:251-6.
[244] Cullander C. What are the pathways of iontophoretic current flow through mammalian
skin? Adv Drug Deliv Rev 1992;9:119-35.
[245] Hirvonen J, Kalia YN, Guy RH. Transdermal delivery of peptides by iontophoresis. Nat
Biotechnol 1996;14:1710-13.
[246] Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery sys-
tems for vitreoretinal diseases. Prog Retinal Eye Res 2004;23:253-81.
[247] Jinsong H, Kevin �, Winston WY, Kao S, Chia-Yang �. Gene delivery to cornea. Brain
Res Bull 2010;81:256-61.
[248] Bloquel C, Bourges J�, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Non-
viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Delivery Rev
2006;58:1224-42.
[249] Asahara T, Shinomiya K, Naito T, Shiota H. Induction of gene into the rabbit eye by
iontophoresis: preliminary report. Jpn J Ophthalmol 2001;45:31-9.
[250] Berdugo M, Valamanesh F, Andrieu C, Klein C, Benezra D, Courtois Y, et al. Delivery
of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid
Drug Dev 2003;13:107-14.
[251] Voigt M, de Kozak Y, Halhal M, Courtois Y, Behar-Cohen F. Down-regulation of NOSII
gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced
uveitis. Biochem Biophys Res Commun 2002;295:336-41.
[252] Andrieu-Soler C, Casas M, Faussat AM, Gandolphe C, Doat M, Tempe D, et al. Stable
transmission of targeted gene modification using single-stranded oligonucleotides with
flanking �NAs. Nucleic Acids Res 2005;33:3733-42.
[253] Hao J, �i SK, �iu CY, Kao WW. Electrically assisted delivery of macromolecules into
the corneal epithelium. Exp Eye Res 2009;89:934-41.
[254] Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, et al.
Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and
in vivo . Gene Ther 2002;9:102-9.
[255] Huth S, �ausier J, Gersting S, Rudolph C, Welsch U, Rosenecker J. Insights into the
mechanisms of magnetofection using PEI-based magnetofections for gene transfer.
J Gene Med 2004;6:923-36.
[256] Gupa PK, Hung CT. Magnetically controlled targeted chemotherapy. In: Willmott N,
Daly J, editors. Microspheres and regional cancer therapy. Boca Raton, F�: CRC Press;
1993. p. 71-116.
[257] Goodwin SC, Bittner CA, Peterson C�, Wong G. Single-dose toxicity study of hepatic
intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug car-
rier. Toxicol Sci 2001;60:177-83.
[258] Krotz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery
to cultured endothelial cells. J Vasc Res 2003;40:425-34.
[259] Krotz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, Plank C. Magnetofection﻽a
highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo . Mol Ther
2003;7:700-10.
[260] Plank C, Schillinger U, Scherer F, Bergemann C, Remy JS, Krotz F, et al. The magnetofec-
tion method: using magnetic force to enhance gene delivery. Biol Chem 2003;384:737-47.